• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO BCT SPECTRA OPTIA; SPECTRA OPTIA IDL SET

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO BCT SPECTRA OPTIA; SPECTRA OPTIA IDL SET Back to Search Results
Catalog Number 12320
Device Problem Insufficient Information (3190)
Patient Problems Convulsion/Seizure (4406); Paresthesia (4421); Cramp(s) /Muscle Spasm(s) (4521)
Event Date 07/12/2023
Event Type  Injury  
Manufacturer Narrative
Lot number and expiry information are not available at this time.Investigation is in process, a follow-up report will be provided.Citation: bray k, lynde c, vu t, et al.Prevalence of baseline hypocalcemia and symptomatic hypocalcemia during leukapheresis.J clin apher.2023;1-10.Doi:10.1002/jca.22076.
 
Event Description
Per journal article "prevalence of baseline hypocalcemia and symptomatic hypocalcemia during leukapheresis" by bray et al.Symptoms of hypocalcemia are reported in up to 50% of patients undergoing leukapheresis procedures.There is no set standard of practice for administering calcium supplementation in the prevention or treatment of hypocalcemia symptoms.The goal of this descriptive, retrospective study was to determine the prevalence of baseline hypocalcemia and symptomatic hypocalcemia during leukapheresis with acid citrate dextrose solution a and to identify patient characteristics associated with symptomatic hypocalcemia.Three percent of patients were found to have hypocalcemia before leukapheresis with 35% experiencing hypocalcemia symptoms during leukapheresis.Older age, higher albumin levels, and longer procedure time were associated with increased risk of hypocalcemia symptoms medical intervention in the form of prophylactic calcium supplementation administered the collection set is not available for return because it was discarded by the customer.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SPECTRA OPTIA
Type of Device
SPECTRA OPTIA IDL SET
Manufacturer (Section D)
TERUMO BCT
lakewood CO 80215
Manufacturer (Section G)
TERUMO BCT
10810 w. collins ave
lakewood CO 80215
Manufacturer Contact
scot hilden
10810 w. collins ave
lakewood, CO 80215
MDR Report Key17768883
MDR Text Key323656864
Report Number1722028-2023-00307
Device Sequence Number1
Product Code LKN
UDI-Device Identifier05020583123205
UDI-Public05020583123205
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K183081
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 09/18/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/18/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number12320
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/24/2023
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-